Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

35,769 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Outpatient clinical pharmacy practice in the face of COVID-19 at a cancer center in New York City.
Yerram P, Thackray J, Modelevsky LR, Land JD, Reiss SN, Spatz KH, Levoir AC, Pak TK, Dao PH, Buege MJ, Derespiris LM, Lau C, Orozco JS, Boparai M, Koranteng LA, Reichert KE, Yan SQ, Daukshus NP, Mathew S, Buie LW, Tizon RF, Freeswick S, Liu D, Harnicar S. Yerram P, et al. Among authors: liu d. J Oncol Pharm Pract. 2021 Mar;27(2):389-394. doi: 10.1177/1078155220987625. Epub 2021 Jan 17. J Oncol Pharm Pract. 2021. PMID: 33459159 Free PMC article.
Immunophenotype and Response to Immunotherapy of RET-Rearranged Lung Cancers.
Offin M, Guo R, Wu SL, Sabari J, Land JD, Ni A, Montecalvo J, Halpenny DF, Buie LW, Pak T, Liu D, Riely GJ, Hellmann MD, Benayed R, Arcila M, Kris MG, Rudin CM, Li BT, Ladanyi M, Rekhtman N, Drilon A. Offin M, et al. Among authors: liu d. JCO Precis Oncol. 2019;3:PO.18.00386. doi: 10.1200/PO.18.00386. Epub 2019 May 16. JCO Precis Oncol. 2019. PMID: 31192313 Free PMC article. No abstract available.
Immune biomarkers and response to checkpoint inhibition of BRAFV600 and BRAF non-V600 altered lung cancers.
Murciano-Goroff YR, Pak T, Mondaca S, Flynn JR, Montecalvo J, Rekhtman N, Halpenny D, Plodkowski AJ, Wu SL, Kris MG, Paik PK, Riely GJ, Yu HA, Rudin CM, Hellmann MD, Land JD, Buie LW, Heller G, Lito P, Yaeger R, Drilon A, Liu D, Li BT, Offin M. Murciano-Goroff YR, et al. Among authors: liu d. Br J Cancer. 2022 Apr;126(6):889-898. doi: 10.1038/s41416-021-01679-1. Epub 2021 Dec 28. Br J Cancer. 2022. PMID: 34963703 Free PMC article.
Characterization of on-target adverse events caused by TRK inhibitor therapy.
Liu D, Flory J, Lin A, Offin M, Falcon CJ, Murciano-Goroff YR, Rosen E, Guo R, Basu E, Li BT, Harding JJ, Iyer G, Jhaveri K, Gounder MM, Shukla NN, Roberts SS, Glade-Bender J, Kaplanis L, Schram A, Hyman DM, Drilon A. Liu D, et al. Ann Oncol. 2020 Sep;31(9):1207-1215. doi: 10.1016/j.annonc.2020.05.006. Epub 2020 May 15. Ann Oncol. 2020. PMID: 32422171 Free PMC article.
Brief Report: Chylothorax and Chylous Ascites During RET Tyrosine Kinase Inhibitor Therapy.
Kalchiem-Dekel O, Falcon CJ, Bestvina CM, Liu D, Kaplanis LA, Wilhelm C, Eichholz J, Harada G, Wirth LJ, Digumarthy SR, Lee RP, Kadosh D, Mendelsohn RB, Donington J, Gainor JF, Drilon A, Lin JJ. Kalchiem-Dekel O, et al. Among authors: liu d. J Thorac Oncol. 2022 Sep;17(9):1130-1136. doi: 10.1016/j.jtho.2022.06.008. Epub 2022 Jul 2. J Thorac Oncol. 2022. PMID: 35788405 Free PMC article.
35,769 results
You have reached the last available page of results. Please see the User Guide for more information.